Patient description: The patient is a 41-year-old obese woman coming to the emergency room with abdominal pain and vomiting. The pain that started gradually yesterday is located in the epigastric and periumbilical regions, radiating to her back. She drinks alcohol frequently and does not smoke. She has no history of allergies and uses only multivitamins daily. Her family history is positive for hypertension (her mother). She lives with her husband and has 3 children. The abdomen is tender and soft. Her bowel sounds are normal. Her heart rate is 115/min and blood pressure 110/75 mmHg. The lab studies are remarkable for leukocytosis (19.5), urea of 8.5, high CRP (145), high amylase (1200) and Glucose level of 15. Her abdominal CT scan revealed acute edematous interstitial pancreatitis with enlarged common bile duct and intrahepatic duct confirming gall stone pancreatitis. Her pregnancy test is negative and she is not breastfeeding.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Myelodysplastic Syndrome With Low-grade Lesions Iron Overload Due to Repeated Red Blood Cell Transfusions Male or female aged ≥ 18 years 2. Have a documented diagnosis of MDS according to WHO 2008 classification (see appendix I), with an International Prognostic Scoring System (IPSS-R) (see Appendix II) of very low, low or intermediate risk. 3. Life expectancy of at least 1 year 4. Serum ferritin level > 1000 ng/mL 5. Prior receipt of ≥20 RBC units 6. Females of childbearing potential must have a negative pregnancy test result month prior to start of dosing, In addition, if applicable, they must Use an effective method of contraception according to local requirements, during the study and within 30 days following their last dose of study medication, OR Have had a tubal ligation (supporting evidence required), OR Have had a hysterectomy (supporting evidence required), OR Participate in a non-heterosexual lifestyle, OR Have a male sexual partner who has been sterilized (supporting evidence required) 7. Non-sterilized heterosexual males and/or their partners must agree to use an effective method of contraception during the study and for 30 days following their last dose of study medication 8. All patients and/or their authorized legal representatives must provide signed and dated written informed consent prior to the first study intervention, and patients must be able to adhere to study restrictions, appointments, and evaluation schedules  IPSS-R prognosis of high and very high risk (to avoid the confounding influence of a high blast count) 2. Unable or unwilling to undergo a 7-day washout period if currently being treated with deferoxamine or deferasirox 3. Evidence of abnormal liver function (serum ALT level > 5 times upper limit of normal or creatinine level >2 times upper limit of normal) 4. A serious, unstable illness, as judged by the investigator, during the past 3 months before screening, including but not limited to: hepatic, renal, gastro-enterologic, respiratory, cardiovascular, endocrinologic, neurologic, or immunologic disease 5. Myocardial infarction, cardiac arrest, or cardiac failure within 1 year before screening 6. QT interval prolongation on ECG 7. Occurrences of severe neutropenia/agranulocytosis (absolute neutrophil count < 0.5 x 109/L 8. History of allergy or sensitivity to deferiprone or related compounds or to other components of the formulation 9. Receipt of any investigational products within the past 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication 10. Participation in any investigational clinical study, other than observational, within the past 30 days; or plans to participate in such a study at any time from the day of enrollment until 30 days post-treatment in the current study 11. History of drug or alcohol abuse within the last 6 months 12. Presence of any medical, psychological, or psychiatric condition which in the opinion of the investigator would cause participation in the study to be unwise 13. Pregnant, breastfeeding, or planning to become pregnant during the study period. 14. Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of study medication 15. Identified as an investigator or other site staff directly affiliated with this study, or an immediate family member (spouse, parent, child, or sibling, whether biological or legally adopted) of either of the above